Effectiveness of icatibant for treatment of hereditary angioedema attacks is not affected by body weight: findings from the Icatibant Outcome Survey, a cohort observational study

Table 5 Evaluation of factors affecting time to treatment^a

Effect (numerator)	Odds ratio	95% CI	P value
Univariate analysis^b
Attack frequency (≥ 10 attacks/year)	2.48	–	< 0.001
BMI (≥ 25 kg/m²)	1.77	–	0.012
Type of administration (HCP)	0.55	–	0.067
Country			< 0.0001^c
Multivariate analysis^d
Attack frequency (≥ 10 attacks/year)^e	2.89	1.36–6.14	0.0056
BMI (≥ 25 kg/m²)^e	1.71	1.06–2.79	0.0295

BMI body mass index; CI confidence interval; HCP health care provider
^aModel of probability that time to treatment < 1 h
^bOnly effects with P < 0.2 are shown. Complete results are presented in Additional file 1: Table S5
^cOverall effect of country on time to treatment
^dOnly significant effects are shown
^eResults were similar when data from the two reinjection outliers were excluded (Additional file 1: Table S6)

ISSN: 2045-7022